Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jun 6;12(11):e026270.
doi: 10.1161/JAHA.122.026270. Epub 2023 May 26.

Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta-Analysis

Huilei Zhao  1 , Ziqi Tan  2 , Menglu Liu  3 , Peng Yu  2 , Jianyong Ma  4 , Xiaozhong Li  5 , Jingfeng Wang  6   7 , Yujie Zhao  3 , Wengen Zhu  8 , Xiao Liu  6   7
Affiliations
Meta-Analysis

Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta-Analysis

Huilei Zhao et al. J Am Heart Assoc. .

Abstract

Background It is still unclear whether there is a sex difference in the prognosis of patients with hypertrophic cardiomyopathy (HCM). Therefore, we performed a meta-analysis to elucidate the association between sex and adverse outcomes in patients with HCM. Methods and Results The PubMed, Cochrane Library, and Embase databases were used to search for studies on sex differences in prognosis in patients with HCM up to August 17, 2021. Summary effect sizes were calculated using a random effects model. The protocol was registered in PROSPERO (International prospective register of systematic reviews) (registration number- CRD42021262053). A total of 27 cohorts involving 42 365 patients with HCM were included. Compared with male subjects, female subjects had a higher age at onset (mean difference=5.61 [95% CI, 4.03-7.19]), a higher left ventricular ejection fraction (standard mean difference=0.09 [95% CI, 0.02-0.15]) and a higher left ventricular outflow tract gradient (standard mean difference=0.23 [95% CI, 0.18-0.29]). The results showed that compared with male subjects with HCM, female subjects had higher risks of HCM-related events (risk ratio [RR]=1.61 [95% CI, 1.33-1.94], I2=49%), major cardiovascular events (RR=3.59 [95% CI, 2.26-5.71], I2=0%), HCM-related death (RR=1.57 [95% CI, 1.34-1.82], I2=0%), cardiovascular death (RR=1.55 [95% CI, 1.05-2.28], I2=58%), noncardiovascular death (RR=1.77 [95% CI, 1.46-2.13], I2=0%) and all-cause mortality (RR=1.43 [95% CI, 1.09-1.87], I2=95%), but not atrial fibrillation (RR=1.13 [95% CI, 0.95-1.35], I2=5%), ventricular arrhythmia (RR=0.88 [95% CI, 0.71-1.10], I2=0%), sudden cardiac death (RR=1.04 [95% CI, 0.75-1.42], I2=38%) or composite end point (RR=1.24 [95% CI, 0.96-1.60], I2=85%). Conclusions Based on current evidence, our results show significant sex-specific differences in the prognosis of HCM. Future guidelines may emphasize the use of a sex-specific risk assessment for the diagnosis and management of HCM.

Keywords: hypertrophic cardiomyopathy; meta‐analysis; prognosis; sex.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flowchart of study selection in the systematic review and meta‐analysis of sex difference in the prognosis of hypertrophic cardiomyopathy.
Other sources include the American College of Cardiology website and Circulation website. HCM indicates hypertrophic cardiomyopathy.
Figure 2
Figure 2. Forest plot showing the differences in age and cardiac function at diagnosis between sexes in patients with hypertrophic cardiomyopathy.
A, Diagnosis age in women and men with hypertrophic cardiomyopathy; B, Left ventricular ejection fraction in women and men with hypertrophic cardiomyopathy; C, Left ventricular outflow tract gradient in women and men with hypertrophic cardiomyopathy. HCM indicates hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; and LVOT, left ventricular outflow tract.
Figure 3
Figure 3. Forest plot for the association between sex and cardiovascular diseases in patients with hypertrophic cardiomyopathy.
A, Forest plot for the association between sex and atrial fibrillation in patients with HCM; B, Forest plot for the association between sex and ventricular arrhythmia in patients with HCM; C, Forest plot for the association between sex and HCM‐related events in patients with HCM; D, Forest plot for the association between sex and major cardiovascular events in patients with HCM. AF indicates atrial fibrillation; and HCM, hypertrophic cardiomyopathy.
Figure 4
Figure 4. Forest plot for the association between sex and death or composite end point in patients with hypertrophic cardiomyopathy.
A, Forest plot for the association between sex and sudden cardiac death in patients with HCM; B, Forest plot for the association between sex and HCM‐related death in patients with HCM; C, Forest plot for the association between sex and cardiovascular death in patients with HCM; D, Forest plot for the association between sex and noncardiac death in patients with HCM; E, Forest plot for the association between sex and all‐cause mortality in HCM; F, Forest plot for the association between sex and composite end point in patients with HCM. HCM indicates hypertrophic cardiomyopathy; and SCD, sudden cardiac death.
See this image and copyright information in PMC

References

    1. Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. Hypertrophic cardiomyopathy: a review. Anesth Analg. 2015;120:554–569. doi: 10.1213/ane.0000000000000538 - DOI - PubMed
    1. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, Udelson JE, Cecchi F, Maron BJ. Gender‐related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480–487. doi: 10.1016/j.jacc.2005.04.043 - DOI - PubMed
    1. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680–1692. - PubMed
    1. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–2218. - PubMed
    1. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387–1398. doi: 10.1161/circulationaha.117.033200 - DOI - PMC - PubMed

Publication types

LinkOut - more resources